Nachrichten und Videos - ALLERGY THERAPEUTICS ORD 0.1P

Allergy Therapeutics plc (“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two pivotal trials Portfolio focus ed on high value growth products to enhance future profitability Ground-breaking Phase I trial of peanut allergy vaccine on track to commence in 2022 following recent FDA clearance of IND application with data expected sooner than previously anticipated P ivotal Phase III...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate ’s Phase I PROTECT trial in H1 2022 Topline data from first-in-human trial expected in H1 2023 A nalysis of data from earlier ex-vivo biomarker study, VLP001 , demonstrate s beneficial mode of action of the vaccine candidate 26 January 20 2...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL Primary endpoint Combined Symptom Medication Score (CSMS) achieved with clinically relevant improvement across both active treatment groups compared to placebo Statistically significant r eduction in CSMS seen in both active treatment groups of 29.1 % and 36.8% compared to...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the Year ended 30 June 2021 Record p re-R&D operating profit ahead of market expectations reflecting continued sales growth Successful ex-vivo VLP Peanut biomarker study showing 24 - fold reduction in allergenicity and beneficial efficacy profile paving the way for first-in-human trial in 2022 Strong cash balance of £40.3m providing sufficient funds with a small amount of debt under...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Trading update O perating profit strong and expected to be well ahead of market expectations E xpenses for 2021 significantly lower than expectations due to C OVID -19 and good cost management . S ome phasing of R&D and commercial costs expected to be carr ied over into 2022 Strong cash position expected at year end S uccessful Immuno BON launch es in Germany and Austria supported by encouraging clinical data 2 4...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the year ended 30 June 2020 Record level of pre R&D operating profit supported by robust sales and operational efficiency Strong cash position with Grass MATA MPL Phase III programme and initial Phase I peanut trial fully funded Exclusive licencing agreement signed for further virus like particle(VLP) candidates 23 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) , Saiba AG (“Saiba”) and DeepVax GmbH (“DeepVax”) Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH Group to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findings Builds on positive ongoing progress in VLP-based peanut...

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard 20-Jul-2020 / 07:30 GMT/BST Hardman & Co Research: Record sales and a COVID-19 wildcard AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short-course subcutaneous allergy immunotherapy (SCIT) platform, which continues to make strong market share gains in a competitive environment. Several products using the PQ...

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth 09-March-2020 / 07:15 GMT/BST Hardman & Co Res earch : Consistent first-half revenue growth AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short course subcutaneous allergy immunotherapy (AIT) platform, which continues to make strong market share gains in a competitive environment. Several products using the...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Interim Results for the six months ended 31 December 2019 Record level of operating profit pre R&D supported by strong sales Strong cash position with Grass MATA MPL Phase III programme fully funded for H2 2020 start Publication of promising preclinical data from VLP Peanut candidate 4 March 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy...

Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”) Allergy Therapeutics publishes encouraging new data for peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology Positive preclinical data package demonstrates positive safety and efficacy profile reducing systemic and local allergic symptoms in a peanut allergy model Manufacturing scale-up for clinical studies to evaluate allergy vaccination using VLP (virus like particle) technology underway 29...

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average 16-Jan-2020 / 08:00 GMT/BST Hardman & Co Res earch : Sales growth well above market average Allergy Therapeutics (AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short course subcutaneous allergy immunotherapy (AIT) platform, which continues to make strong market share gains in a competitive environment....

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share 26-Sep-2019 / 07:30 GMT/BST Hardman & Co Res earch : Continuing to gain market share Allergy Therapeutics (AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, the ultra-short course subcutaneous allergy immunotherapy (AIT), continues to gain market share, despite its availability in the EU only on a "named-patient"...

DGAP-News: Allergy Therapeutics plc / Schlagwort(e): Umsatzentwicklung Allergy Therapeutics plc veröffentlicht Update zur Geschäftsentwicklung 19.07.2019 / 11:33 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Allergy Therapeutics plc veröffentlicht Update zur Geschäftsentwicklung - Finanzergebnisse über den Markterwartungen; Marktanteil weiter wachsend - Erstes Treffen mit Aufsichtsbehörden zur Vorbereitung der klinischen Studie Phase I für einen Impfstoff...

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty 01-Jul-2019 / 07:20 GMT/BST Hardman & Co: Successful legal outcome removes uncertainty AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, an ultra-short-course subcutaneous allergy immunotherapy (SCIT), continues to gain market share despite its availability in the EU on a 'named-patient' (NP) basis...

Hardman & Co Research Hardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value 01-Jul-2019 / 07:15 GMT/BST Hardman & Co: Eying up long-term value Oxford BioMedica (OXB) is a specialist, advanced therapy, viral-vector biopharma company. It offers vector manufacturing and development services, while developing proprietary drug candidates, with its LentiVector(R) platform. 2018 saw significant growth in gross income, the majority through licensing deals. A new R&D collaboration deal...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Successful litigation settlement relating to PQ Grass Phase II Trial 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it has received a $7.6m settlement from Inflamax Research Inc. (“Inflamax”) in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which...

Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”) Trading Update and Successful Litigation Settlement 2019 full year earnings expected to be ahead of market expectations 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces a pre-close trading update for the 12 months ended 30 June 2019 and the successful outcome of the litigation related to the Grass MATA MPL Phase II...

Hardman & Co Research Hardman & Co Research: Titon Holdings Plc (TON): You need hands 21-May-2019 / 08:30 GMT/BST Hardman & Co Research: You need hands Failure to applaud is the original meaning of the idiom 'to sit on your hands'; it originated in the theatre, when an unimpressed audience refused to clap. In the modern lexicon, it means to remain idle when things go awry and when action is required. Titon has had a charmed run over the past three years but this year has met with a tough South...

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): House dust mite vaccine - clinical progress 21-May-2019 / 07:15 GMT/BST Hardman & Co: House dust mite vaccine - clinical progress AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, an ultra-short-course subcutaneous allergy immunotherapy (SCIT), continues to gain market share despite its availability in the EU on a 'named-patients' (NP) basis...